We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Does the CHA2DS2-VASc score determine anticoagulant treatment in atrial fibrillation patients? Data from the POLish Atrial Fibrillation (POL-AF) Registry.
- Authors
Szpotowicz, Anna; Gorczyca-Głowacka, Iwona; Uziębło-Życzkowska, Beata; Maciorowska, Małgorzata; Wójcik, Maciej; Błaszczyk, Robert; Kapłon-Cieślicka, Agnieszka; Gawałko, Monika; Budnik, Monika; Tokarek, Tomasz; Rajtar-Salwa, Renata; Bil, Jacek; Wojewódzki, Michał; Bednarski, Janusz; Bakuła-Ostalska, Elwira; Tomaszuk-Kazberuk, Anna; Szyszkowska, Anna; Wełnicki, Marcin; Mamcarz, Artur; Krzciuk, Małgorzata
- Abstract
Introduction. Oral anticoagulants (OAC) should be used in patients with atrial fibrillation (AF) depending on the thromboembolic risk assessed using the CHA2DS2-VASc score. The aim of the study is to verification if the CHA2DS2-VASc score influences using OACs in patients with AF and also to analyse predictors of OAC use in AF patients at non-high (intermediate and low) thromboembolic risk. Material and methods. The presented study has been based on the data from the POL-AF Registry which is a prospective, multicentre study including patients with diagnosed AF consecutively hospitalized in 10 cardiology centres from January to December 2019. Results. The study comprised 3,956 patients. A high risk of thromboembolic complications was observed in 91.4%, intermediate in 6.3% and low in 2.3% of them. OACs were administered to 81.1% of patients, including 91.5% at high, 90.3% at intermediate and 86.2% at low thromboembolic risk. CHA2DS2-VASc score was not a predictor of using OACs in all patients with AF [odds ratio (OR) 1.02, confidence interval (CI): 0.96-1.08, p = 0.747]. In the group of patients with non-high thromboembolic risk, the factor predisposing to OAC prescription was hospitalization due to electrical cardioversion [OR 6.55, CI: 1.52-28.21, p = 0,012], contrary to anaemia (OR 0.27, CI: 0.12-0.64, p = 0,003) and cancer (OR 0.14, CI: 0.03-0.57, p = 0.006), which decreased the chance of using OACs in this group. Conclusions. The CHA2DS2-VASc score was not a predictor of OAC use in the whole study cohort. In the significant proportion of non-high thromboembolic risk patients with AF, OACs were administered, mainly because of temporary indications.
- Subjects
ANTICOAGULANTS; ATRIAL fibrillation; HOSPITAL patients; CARDIOLOGY; ANEMIA; RISK assessment
- Publication
Folia Cardiologica, 2021, Vol 16, Issue 6, p1
- ISSN
2353-7752
- Publication type
Article
- DOI
10.5603/FC.a2021.0053